Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up

NCT04155749 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.

NCT NCT04155749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04155749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Lead sponsor
Kite, A Gilead Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 23, 2019
Completion date
May 31, 2027
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and refractory multiple myeloma